Amgen's cholesterol fighter succeeds in fifth late-stage study

(Reuters) - Amgen Inc said its experimental drug from a promising new class of injectable medicines succeeded in treating patients with genetically high cholesterol levels, marking the fifth successful clinical study of the drug. Evolocumab met the main goal of a late-stage trial titled RUTHERFORD-2 by lowering "bad" LDL cholesterol levels when tested against a placebo on 329 patients. Amgen, the world's biggest biotechnology company, is testing evolocumab widely on a variety of subpopulations. The RUTHERFORD-2 study included patients with familial hypercholesterolemia, an inherited condition that causes high levels of "bad" LDL cholesterol starting at birth.



via Health News Headlines - Yahoo News http://ift.tt/1gv6ZvV